Novo Nordisk: Selloff Sparks Bullish Upgrade, But DeepValue Report Warns of Persistent Risks

What happened

Novo Nordisk's stock has fallen 38% over the past year, leading to a Seeking Alpha upgrade to 'Strong Buy' as the author views the decline as a compelling entry point given the company's GLP-1 portfolio and strategic moves like the Akero acquisition. However, the latest DeepValue master report rates NVO a 'Potential Buy' with only 3.5 conviction, highlighting that the stock at $45.9 trades at 10.9x P/E and 9.3x EV/EBITDA, reflecting market expectations of sustained share loss and structural US net-price compression. The report emphasizes that while oral Wegovy's launch and the $4.2B 340B revenue recognition provide near-term support, the key question remains whether oral Wegovy will expand the total patient pool or merely cannibalize injectables while anchoring a $149/month cash-pay reference price. Additionally, risks such as payer coverage tightening (e.g., Cigna's July 2026 action) and ongoing volume share losses to Eli Lilly continue to weigh on the outlook. The combination of the bull case from the article and the guarded analysis from the deep-value perspective suggests that while the selloff may offer a discounted entry, investors must closely monitor oral Wegovy prescription trends and competitive dynamics over the next 6-12 months.

Implication

For investors considering NVO, the recent ~38% decline offers a potential entry point at a compelling valuation, but the reward hinges on observable proof points over the next 6-12 months: oral Wegovy must sustain its ~33% mix of total Wegovy prescriptions and show that it expands the treatable patient population, not just substitutes for injectables. The $4.2B 340B revenue recognition in Q1 2026 provides a temporary earnings boost, but this is a one-time catch-up, not a recurring tailwind. The bear case, with an implied value of $38, becomes more likely if additional large employers follow Cigna's lead in dropping GLP-1 coverage or if oral Wegovy's mix declines without total script growth. Conversely, the bull case of $60 hinges on successful ex-US oral launches, stable or improving reimbursement, and evidence that volume growth can offset net price compression. Therefore, a measured, partial entry with a plan to re-assess by Q4 2026 based on prescription data and payer actions is warranted, rather than a full commitment at current levels.

Thesis delta

The Seeking Alpha article upgrades NVO to Strong Buy, arguing the selloff is overdone and that the long-term tailwinds from oral Wegovy and pipeline progress are undervalued. While the DeepValue report acknowledges the potential for upside, it maintains a more cautious stance, emphasizing that the stock already discounts significant earnings pressure and that observable data over the next two quarters will determine whether the bull case materializes. The key shift is that the recent price decline has improved the risk-reward, but the thesis has not fundamentally changed—it still depends on the same critical proof points around oral Wegovy adoption and payer dynamics.